Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene ExpressionDavid A. Jacobsohn, Michael A. Pulsipher, Morris Kletzel et al.|Transplantation and Cellular Therapy|2018Cited by 44
Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant ConsortiumEneida R. Nemecek, Colleen Delaney, Ralf A. Hilger et al.|Transplantation and Cellular Therapy|2018Cited by 21
Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre‐transplant minimal residual disease reductionNirali N. Shah, Alan S. Wayne, Denison Kuruvilla et al.|Pediatric Blood & Cancer|2020Cited by 5
Phase II Study of Treosulfan/Fludarabine/ Low Dose Total Body Irradiation As a Preparative Regimen for Children with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing Allogeneic Hematopoietic Cell TransplantationEneida R. Nemecek, Colleen Delaney, Alexia Adams et al.|Transplantation and Cellular Therapy|2016Cited by 0